Imipenem/cilastatin: Pharmacokinetic profile in renal insufficiency☆
References (17)
- et al.
Kinetics of procainamide and N-acetylprocainamide in renal failure
Kidney Int
(1977) Metabolism of drugs by the kidney
Kidney Int.
(1980)- et al.
The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure
Br J Clin Pharmacol
(1984) - et al.
Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK 0787) in humans
Antimicrob Agents Chemother
(1983) - et al.
Disposition of radiolabeled imipenem and cilastatin in normal human volunteers
Antimicrob Agents Chemother
(1984) - et al.
- et al.
Kinetics of N-acetylprocainamide deacetylation
Clin Pharmacol Ther
(1980) - et al.
Drug kinetics and artificial kidneys
Clin Pharmacokinet
(1972)
There are more references available in the full text version of this article.
Cited by (66)
Predicting the Effect of Renal Function on Systemic Clearance: Is a Simple Scaling Method Sufficient?
2023, Journal of Pharmaceutical SciencesDoes dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review
2021, Clinical Microbiology and InfectionCitation Excerpt :The inclusion criteria were met for 25 studies; additionally, two studies were identified by manually screening the reference lists. Ultimately 27 studies were included [19–45]. The main reason for exclusion of studies was that the administered dose of antibiotics was not reduced in patients with impaired renal function (Fig. 1).
Principles of Drug Therapy, Dosing, and Prescribing in Chronic Kidney Disease and Renal Replacement Therapy
2010, Comprehensive Clinical Nephrology: Fourth EditionEffects of renal failure on drug transport and metabolism
2006, Pharmacology and TherapeuticsCarbapenems and monobactams: Imipenem, meropenem, and aztreonam
1999, Mayo Clinic ProceedingsCan non-renal clearance and/or bioavailability of drugs be assessed reliably in renal impairment studies with oral drug administration?
2024, International Journal of Clinical Pharmacology and Therapeutics
- ☆
This work was supported by a grant from Merck Sharp and Dohme and the Research and Development Service of the Veterans Administration.
Copyright © 1985 Published by Excerpta Medica Inc.